Moderna said on Monday its experimental influenza vaccine showed superior efficacy compared with a licensed standard-dose ...

Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus ...

The Department of Agriculture has issued its first-ever permit to vaccinate poultry against highly pathogenic avian influenza ...

An mRNA-based seasonal flu vaccine from Moderna was 27 percent more effective at preventing influenza infections than a ...

The CDC panel voted against an ingredient that the anti-vaccine movement has long targeted, while Arcadia was acquired by ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Moderna's flu vaccine candidate, mRNA-1010, shows 26.6% efficacy in a Phase 3 trial for adults 50+. Read more here.

In parallel, Guyana began weekly reporting of surveillance data to the Pan American Health Organization (PAHO)/World Health Organization (WHO) via FluNet and ...

Taking aim at a longtime target of anti-vaccine activists, CDC advisors said Thursday that the U.S. should not administer ...

A long-lasting formulation of an antiviral drug greatly reduced people’s risk of a symptomatic flu infection in a trial, and ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.